Emerging frontiers in glioma therapy: the evolving role of glioma vaccines

Glioma, particularly glioblastoma (GBM), remains one of the most lethal primary brain tumors, characterized by aggressive biological behavior, profound intratumoral heterogeneity, and a highly immunosuppressive tumor microenvironment. Despite encouraging advances in cancer immunotherapy, durable clinical benefit from glioma vaccines has remained limited, highlighting a substantial translational gap between early immunogenicity and long-term therapeutic efficacy. In this review, we provide an integrative overview of current glioma vaccine strategies, including peptide-based, dendritic cell-based, nucleic acid-based, and autologous tumor-derived platforms, with a particular focus on their biological rationale, clinical performance, and translational limitations. Rather than merely summarizing recent developments, we critically examine the shared factors that have constrained clinical success, including antigen heterogeneity, immune escape, HLA restriction, treatment-related immunosuppression, and the inhibitory effects of the glioma tumor microenvironment. We further discuss how these challenges have shaped the emerging rationale for combination strategies involving vaccines with chemotherapy, anti-angiogenic agents, immune checkpoint blockade, and other immunotherapeutic modalities. Finally, we highlight forward-looking design principles for next-generation glioma vaccines, including improved antigen selection, biomarker-guided patient stratification, microenvironment-aware therapeutic design, and more predictive translational models. Overall, we propose that future progress in glioma vaccine therapy will depend not only on improving vaccine platforms themselves, but also on integrating them into biologically rational and clinically informed therapeutic frameworks.